These studies suggest that HDAC inhibition may sensitize some breast cancer subtypes to DNA-damaging agents, including radiotherapy, although a more thorough investigation is necessary to determine the broader implications of these studies. The gene discussed is HDAC9; the disease is breast carcinoma.